A Multicenter, Open-label Extended Access Program (EAP) of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Expanded access
- Sponsors Celgene Corporation
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
- 02 Feb 2015 New trial record